Research and Markets: Uterine Leiomyoma (Uterine Fibroids) Pipeline Review 2015 - 11 Companies & 15 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/2m9jz4/uterine_leiomyoma) has announced the addition of the "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• AbbVie Inc.
• Bayer AG
• BioSpecifics Technologies Corp.
• Dongkook Pharmaceutical Co., Ltd.
• Euroscreen S.A.
• Kissei Pharmaceutical Co., Ltd.
• Laboratoire HRA Pharma
• Neurocrine Biosciences, Inc.
• Novartis AG
• Repros Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
  

Drug Profiles

• collagenase clostridium histolyticum
• Drug to Activate Progesterone Receptor for Uterine Fibroids
• Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma
• elagolix sodium
• ESN-364
• EVE-104
• KLH-2109
• LFA-102
• mifepristone
• relugolix
• Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology
• telapristone acetate
• triptorelin pamoate biosimilar
• ulipristal acetate
• vilaprisan

For more information visit http://www.researchandmarkets.com/research/2m9jz4/uterine_leiomyoma